The regulation of the proximal step in the immune response, antigen presentation by dendritic cells, determines the immunological outcome of encounter with antigen: tolerance vs. activation of the cellular and/or humoral response. Dendritic cells express several receptors for the Fc portion of immunoglobulin G (FCgammaR), which facilitate this process by internalization of antigen-IgG complexes (immune complexes, ICs), induction of dendritic cell maturation, and enhancement of major histocompatibility complex (MHC) class I- and class II-restricted antigen presentation. Thus FcgammaR mediated antigen presentation accomplishes a long-sought goal in tumor-vaccine design, combined activation of both CD4 and CD8 T cell pathways. In experiments demonstrating the importance of the FcgammaR antigen presentation pathway in vivo, our preliminary data indicate that dendritic cells loaded with antibody-opsonized tumor cells or Ova-containing ICs induce T cell activation in vivo and rejection of Ova-bearing tumors in mice. Furthermore, tumor prevention is accompanied by the induction of both class II and class I restricted CD4 and CD8 T cell responses. FcgammaR-mediated trapping and endocytosis of immune complexes has been known to efficiently induce class II restricted antibody responses, however, this is the first demonstration in vivo of an endocytically acquired antigen, in this case immune complex uptake, resulting in """"""""cross-priming"""""""" or the induction of a class I restricted cellular immune response. This link of ICs and class I responses suggests that antibody produced during an initial exposure to antigen during an ongoing immune response may provide the host further protection by initiation of a subsequent T cell-mediated cellular response, and suggests novel approaches to tumor vaccine development.
Our specific aims are to: 1) Determine the mechanism of tumor protection and specifically whether activating and inhibitory FcgammaRs coordinately regulate CD8 and Th1 -polarized CD4 responses. 2) Establish the potency and general applicability of IC-loaded dendritic cell vaccination approaches to HER2 transgenic models of breast cancer. 3) Determine whether FcgammaR uptake enhances class I antigen presentation in human systems and specifically whether antibody-mediated T cell priming occurs in Trastuzumab-treated patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA094037-03
Application #
6767552
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Howcroft, Thomas K
Project Start
2002-08-01
Project End
2007-07-31
Budget Start
2004-08-20
Budget End
2005-07-31
Support Year
3
Fiscal Year
2004
Total Cost
$327,409
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Budhu, Sadna; Loike, John D; Pandolfi, Ashley et al. (2010) CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 207:223-35
Liang, Bitao; Workman, Craig; Lee, Janine et al. (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180:5916-26
He, Li-Zhen; Crocker, Andrea; Lee, Janine et al. (2007) Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 178:6259-67
Harbers, Stephanie O; Crocker, Andrea; Catalano, Geoffrey et al. (2007) Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117:1361-9
Desai, Dharmesh D; Harbers, Stephanie O; Flores, Marcella et al. (2007) Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 178:6217-26
Taylor, Clare; Hershman, Dawn; Shah, Nina et al. (2007) Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133-43